Accès libre

Association of OPRM1, MIR23B, and MIR107 genetic variability with acute pain, chronic pain and adverse effects after postoperative tramadol and paracetamol treatment in breast cancer

Zala Vidic
Zala Vidic
, 
Katja Goricar
Katja Goricar
, 
Branka Strazisar
Branka Strazisar
, 
Nikola Besic
Nikola Besic
 et 
Vita Dolzan
Vita Dolzan
   | 22 mars 2023
Radiology and Oncology's Cover Image
À propos de cet article
Article précédent
Article suivant
Citez
Article Category: Research Article
Publié en ligne: 22 mars 2023
Pages: 111 - 120
Reçu: 14 sept. 2022
Accepté: 28 sept. 2022
DOI: https://doi.org/10.2478/raon-2023-0003
© 2023 Zala Vidic, Katja Goricar, Branka Strazisar, Nikola Besic, Vita Dolzan, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

The impact of investigated polymorphisms on chronic and neuropathic pain (N = 101)

SNP Genotype Chronic N (%) pain OR (95% CI) P OR (95% CI)adj Padj
OPRM1 rs1799971 AA 15 (20.3) Ref. Ref.
AG+GG 6 (22.2) 1.12 (0.39–3.28) 0.831 1.2 (0.4–3.57) 0.739
OPRMrs677830 1 CC 14 (27.5) Ref. Ref.
CT+TT 7 (14) 0.43 (0.16–1.18) 0.101 0.44 (0.16–1.21) 0.112
MIR23B rs1011784 CC 9 (15.3) Ref. Ref.
CG 10 (32.3) 2.65 (0.94–7.45) 0.065 2.85 (0.99–8.19) 0.052
GG 2 (20) 1.39 (0.25–7.64) 0.706 1.68 (0.29–9.83) 0.563
MIR107 rs2296616 CG+GG GG 12 (29.3) 0 (0) 2.3 (0.86–6.11) Ref. 0.095 2.58 (0.94–7.1) Ref. 0.067
GA 9 (18.4) / 0.099*
AA 12 (35.3) / 0.004*
GA+AA 21 (25.3) / 0.021*
SNP Genotype Neuropathic pain N (%) OR (95% CI) P OR (95% CI)adj Padj
OPRM1 rs1799971 AA 19 (25.7) Ref. Ref.
AG+GG 6 (22.2) 0.83 (0.29–2.36) 0.722 0.94 (0.32–2.75) 0.915
OPRMrs677830 1 CC 17 (33.3) Ref. Ref.
CT+TT 8 (16) 0.38 (0.15–0.99) 0.047 0.4 (0.15–1.04) 0.060
MIR23B rs1011784 CC 11 (18.6) Ref. Ref.
CG 12 (38.7) 2.76 (1.04–7.31) 0.042 3.25 (1.17–9.02) 0.023
GG 2 (20) 1.09 (0.2–5.87) 0.919 1.59 (0.27–9.24) 0.607
CG+GG 14 (34.1) 2.26 (0.9–5.68) 0.082 2.85 (1.07–7.59) 0.036
MIR107 rs2296616 GG 3 (16.7) Ref. Ref.
GA 11 (22.4) 1.45 (0.35–5.93) 0.607 1.37 (0.33–5.69) 0.666
AA 11 (32.4) 2.39 (0.57–10.02) 0.233 2.34 (0.55–9.97) 0.249
GA+AA 22 (26.5) 1.8 (0.48–6.83) 0.386 1.73 (0.45–6.65) 0.424

Patients’ clinical characteristics
All subjects
 Stronger postoperative analgesia with tramadol/paracetamol
 Weaker postoperative analgesia with tramadol/paracetamol
Sample size
N = 113
 N = 55
 N = 58
Characteristic N (%) N (%) N (%)
Age (years) Median (25–75 %) 55 (48–63) 57 (49–64) 53,5 (47.8–61)
Weight (kg) Median (25–75 %) 72 (63.5–82) 72 (64–82) 72 (63–82.3)
Body Mass Index (kg/m2) Median (25–75 %) 27.1 (23.4–31.0) 26.7 (23.0–30.8) 27.6 (23.5–31.2)
Smoking No 87 (77.7) [1] 41 (75.9) [1] 46 (79.3)
Yes 25 (22.3) 13 (24.1) 12 (20.7)
ASA score 1 22 (19.6) [1] 10 (18.2) 12 (21.1) [1]
2 81 (72.3) 39 (70.9) 42 (73.7)
3 9 (8.0) 6 (10.9) 3 (5.3)
Side of the operation Left 62 (54.9) 30 (54.5) 32 (55.2)
Right 50 (44.2) 24 (43.6) 26 (44.8)
Bilateral 1 (0.9) 1 (1.8) 0 (0.0)
Tumor grade 1 4 (3.6) [1] 1 (1.9) [1] 3 (5.2)
1–2 3 (2.7) 2 (3.7) 1 (1.7)
2 39 (34.8) 17 (31.5) 22 (37.9)
2–3 8 (7.1) 2 (3.7) 6 (10.3)
3 58 (51.3) 32 (59.3) 26 (44.8)
VAS after 7 days Median (25–75 %) 2 (1–3) [5] 1.3 (1–2) [3] 2 (1–3) [2]
VAS after 14 days Median (25–75 %) 1.5 (0–2) [11] 1 (0–2) [9] 2 (1–2) [2]
VAS after 21 days Median (25–75 %) 1 (0.4–2) [11] 1 (0–2) [9] 1 (1–2) [2]
VAS after 28 days Median (25–75 %) 1 (0–2) [14] 1 (0–1) [10] 1 (1–2) [4]

The investigated polymorphism’s characteristics and frequencies

Gene SNP Genotype N (%) PAF (%) MAF HapMap CEU expected (%) PHWE
OPRM1 rs1799971 AA 84 (74.3) 14.2 15.6–16.7 0.570
AG 26 (23.0)
GG 3 (2.7)
rs677830 CC 56 (49.6) 27.4 20.7 0.098
CT 52 (46.0)
TT 5 (4.4)
MIR23B rs1011784* CC 63 (56.3) [1] 26.8 23.3 0.153
CG 38 (33.9)
GG 11 (9.8)
MIR107 rs2296616* GG 21 (18.6) 57.1 54.2–55.3 0.944
GA 55 (48.7)
AA 37 (32.7)

The impact of investigated polymorphisms on constipation anytime during the first four weeks of tramadol treatment (N = 99)

SNP Genotype Constipation anytime N (%) OR (95% CI) P OR (95% CI)adj Padj
OPRM1 rs1799971 AA 30 (40) Ref. Ref.
AG+GG 18 (75) 4.5 (1.6–12.64) 0.004 4.31 (1.52–12.17) 0.006
OPRM1 rs677830 CC 24 (48) Ref. Ref.
CT+TT 24 (49) 1.04 (0.47–2.29) 0.922 0.98 (0.44–2.19) 0.964
MIR23B rs1011784 CC 29 (50) Ref. Ref.
CG 16 (50) 1 (0.42–2.37) 1.000 0.96 (0.4–2.31) 0.930
GG 3 (37.5) 0.6 (0.13–2.75) 0.510 0.46 (0.1–2.23) 0.338
CG+GG 19 (47.5) 0.9 (0.4–2.03) 0.808 0.84 (0.37–1.91) 0.676
MIR107 rs2296616 GG 11 (57.9) Ref. Ref.
GA 23 (48.9) 0.7 (0.24–2.04) 0.511 0.73 (0.25–2.16) 0.566
AA 14 (42.4) 0.54 (0.17–1.68) 0.285 0.53 (0.17–1.67) 0.276
GA+AA 37 (46.3) 0.63 (0.23–1.72) 0.364 0.64 (0.23–1.77) 0.386

The impact of investigated miRNA polymorphisms on nausea after 21 and 28 days of tramadol treatment (N = 99)

SNP Genotype Nausea days N (%) 21 OR (95% CI) P Nausea days N (%) 28 OR (95% CI) P
MIRrs1011784 23B CC 9 (16.4) Ref. 4 (7.5) Ref.
CG 4 (12.9) 0.76 (0.21–2.7) 0.668 5 (16.1) 2.36 (0.58–9.54) 0.230
GG 2 (25) 1.7 (0.3–9.83) 0.551 3 (37.5) 7.35 (1.27–42.6) 0.026
CG+GG 6 (15.4) 0.93 (0.3–2.86) 0.898 8 (20.5) 3.16 (0.88–11.39) 0.078
MIRrs2296616 107 GG 6 (31.6) Ref. 2 (10.5) Ref.
GA 4 (8.9) 0.21 (0.05–0.87) 0.031 4 (8.7) 0.81 (0.14–4.84) 0.817
AA 5 (16.7) 0.43 (0.11–1.69) 0.229 6 (21.4) 2.32 (0.41–12.96) 0.338
GA+AA 9 (12) 0.30 (0.09–0.97) 0.045 10 (13.5) 1.33 (0.27–6.64) 0.730
eISSN:
1581-3207
Langue:
Anglais
Périodicité:
4 fois par an
Sujets de la revue:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology
RSS Feed de la revue